LDL-cholesterol versus non-HDL-to-HDL-cholesterol ratio and risk for coronary heart disease in type 2 diabetes

European Journal of Preventive Cardiology

Volumn 21, Issue 11, 2014, Pages 1420-1428

  Eliasson, B ^a   Gudbjornsdottir S ^a   Zethelius, B ^b   Eeg Olofsson, K ^a   Cederholm, J ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

coronary heart disease; Diabetes mellitus; epidemiology; human; LDL cholesterol; lipoproteins; non HDL cholesterol

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; DIABETIC PATIENT; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; RISK FACTOR; BLOOD; COMPARATIVE STUDY; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK ASSESSMENT; STATISTICAL MODEL; SWEDEN; TIME;

ADULT; AGED; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SWEDEN; TIME FACTORS;

EID: 84908891471     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487313494292     Document Type: Article

References (41)

1. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004 ; 110: 227-239
2. Standards of Medical Care in Diabetes 2013. Diabetes Care. 2013 ; 36: S4 - S10
3. European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2012 ; 33: 1635-1701
4. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 2002; 106: 3143-3421.
5. ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2011 ; 32: 1769-1818
6. Simon A, Chironi G, Gariepy J, et al. Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical atherosclerosis in asymptomatic men. Atherosclerosis. 2005 ; 179: 339-344
7. Ndumele CE, Matsushita K, Astor B, et al. Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: The ARIC study. Eur J Prev Cardiol. Epub ahead of print October 29 2012.
8. Frontini MG, Srinivasan SR, Berenson G, et al. Utility of non-high-density lipoprotein cholesterol versus other lipoprotein measures in detecting subclinical atherosclerosis in young adults (The Bogalusa Heart Study). Am J Cardiol. 2007 ; 100: 64-68
9. Orakzai SH, Nasir K, Blaha M, et al. Non-HDL cholesterol is strongly associated with coronary artery calcification in asymptomatic individuals. Atherosclerosis. 2009 ; 202: 289-295
10. Toth PP, Simko RJ, Rao Palli S, et al. The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus. Cardiovasc Diabet. 2012 ; 11: 109-119
11. Brunzell JD, Davidson M, Furberg CD. Lipoprotein management in patients with cardiometabolic risk. J Am Coll Cardiol. 2008 ; 51: 1512-1524
12. Ingelsson E, D'Agostino RB, Vasan RS, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA. 2007 ; 298: 776-785
13. Nam B-H, Kannel WB, D'Agostino RB. Search for an optimal atherogenic lipid risk profile: From the Framingham Study. Am J Cardiol. 2006 ; 97: 372-375
14. Jiang R, Schulze MB, Hu FB, et al. Non-HDL cholesterol and apolipoprotein b predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care. 2004 ; 27: 1991-1997
15. Taskinen MR, Barter PJ, Ehnholm C, et al. Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia. 2010 ; 53: 1846-1855
16. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986 ; 256: 2835-2838
17. Sacks FM, Tonkin AM, Craven T, et al. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triacylglycerol as risk factors. Circulation. 2002 ; 105: 1424-1428
18. deGoma EM, Leeper NJ, Heidenreich PA. Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol. 2008 ; 51: 49-55
19. Stevens RJ, Adler AI, Holman RR, et al. The UKPDS Risk Engine: A model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci. 2001 ; 101: 671-679
20. Zethelius B, Eliasson B, Cederholm J, et al. A new model for 5-year risk of cardiovascular disease in type 2 diabetes - from the Swedish National Diabetes Register (NDR). Diab Res Clin Pract. 2011 ; 93: 276-284
21. Gudbjörnsdottir S, Eliasson B, Cederholm J, et al. Additive effects of glycaemia and dyslipidaemia on risk of cardiovascular diseases in type 2 diabetes: An observational study from the Swedish National Diabetes Register. Diabetologia. 2011 ; 54: 2544-2551
22. Eliasson B, Cederholm J, Gudbjörnsdottir S, et al. Clinical usefulness of different lipid measures for prediction of coronary heart disease in type 2 diabetes: A report from the Swedish National Diabetes Register. Diabetes Care. 2011 ; 34: 2095-2100
23. Eriksson M, Cederholm J, Eliasson B, et al. Blood lipids in 75048 type 2 diabetic patients: a population-based survey from the Swedish National Diabetes Register. Eur J Cardiovasc Prev Rehab. 2011 ; 18: 97-105
24. Hoelzel W, Weykamp C, Jeppsson JO, et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: A method-comparison study. Clin Chem. 2004 ; 50: 166-174
25. Merlo J, Lindblad U, Pessah-Rasmussen H, et al. Comparison of different procedures to identify probable cases of myocardial infarction and stroke in two Swedish prospective cohort studies using local and national routine registers. Eur J Epidemiol. 2000 ; 16: 235-243
26. Cederholm J, Zethelius B, Gudbjörnsdottir S, et al. Different methods to present the effect of blood pressure on cardiovascular diseases by Cox regression. J Hypertens. 2012 ; 30: 235-237
27. Holman RR, Coleman RL, Stevens RJ, et al. Non-HDL cholesterol is less informative than the total-to-HDL cholesterol ratio in predicting cardiovascular risk in type 2 diabetes. Diabetes Care. 2005 ; 28: 1796-1797
28. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010 ; 376: 1670-1681
29. Hayward RA, Hofer TP, Vijan S. Narrative review: Lack of evidence for recommended low-density lipoprotein treatment targets: A solvable problem. Ann Intern Med. 2006 ; 145: 520-530
30. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 ; 344: 1383-1389
31. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: a randomized controlled trial. JAMA. 2005 ; 294: 2437-2445
32. LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005 ; 352: 1425-1435
33. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 ; 359: 2195-2207
34. Taskinen MR. Type 2 diabetes as a lipid disorder. Curr Mol Med. 2005 ; 5: 297-308
35. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007 ; 357: 2109-2122
36. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011 ; 365: 2255-2267
37. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study. Lancet. 2012 ; 380: 572-580
38. Sorrentino SA, Besler C, Rohrer L, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type-2-diabetes-mellitus but are improved after extended-release niacin therapy. Circulation. 2010 ; 121: 110-122
39. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999 ; 341: 410-418
40. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010 ; 362: 1563-1574
41. Eliasson B, Svensson A-M, Gudbjörnsdottir S, et al. Clinical use and effectiveness of lipid lowering therapies in diabetes mellitus - An observational study from the Swedish National Diabetes Register. PLOS One. 2011 ; 6: 1-9